Clinical Trial Update: Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of erlotinib hydrochloride in bladder cancer patients undergoing surgery was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Erlotinib hydrochloride (Erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Bladder Carcinoma, Recurrent Bladder Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2020-07-07